Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T-DM1

- PMLiVE

Roche gains speedy review for Tecentriq in first-line breast cancer

Set to become the first immunotherapy for triple negative breast cancer

- PMLiVE

Soon-Shiong presents first data on cancer memory vaccine at SITC

Novel cocktail shows modest gains in prostate cancer

Roche Basel Switzerland

Roche and AbbVie prepare to move Venclexta into first-line CLL

Data shows an extended PFS compared to those on Gazyva plus chlorambucil chemo

- PMLiVE

Is GSK planning to exit the respiratory business?

Oncology head says opportunities diminishing despite firm's heritage

- PMLiVE

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Company faces pressure from competitors in renal cell carcinoma

- PMLiVE

Roche’s new flu pill Xofluza approved in US

First novel treatment in decades, but hasn't shown superiority to Tamiflu

- PMLiVE

AZ swells immuno-oncology pipeline with Innate deal

Deal gives access to natural killer cell immunotherapy

- PMLiVE

Merck’s Bavencio joins first-line kidney cancer face-off

PD-L1 and TKI combination could challenge standard of care

- PMLiVE

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Contrasting results for two novel immunotherapies

Roche Basel Switzerland

Roche preps new Kadcyla filings after phase 3 trial win

Says the drug significantly reduced IDFS in women with residual disease

- PMLiVE

Ocrevus surge keeps Roche smiling in Q3

MS drug is performing well, but immuno-oncology contender is in the doldrums

- PMLiVE

Cancer care – the power of new technologies

With patient numbers set to soar, how can we make a difference?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links